Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C
Status:
Unknown status
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
It is a multi-center study of the efficacy of a new Pegylated Hansenula-derived recombinant
interferon α 2a (Reiferon Retard® 160 µg once weekly in combination with ribavirin in
treatment of Egyptian patients with chronic hepatitis C for 48 weeks.
hepatitis C virus (HCV) viral load will be assessed during therapy at weeks 12, 24 and end of
treatment, as well as 24 weeks after therapy is completed.